AYJ0.F VALNEVA SE SP.ADS/2

Healthcare Biotechnology Frankfurt Exchange
4.92 EUR
Close of Nov 11, 2026
3.84 10.00
Market cap
EUR 468M
P/E
-
P/B
5.98x
ROE
-156.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AYJ0.F undervalued?

Graham number

The Graham number of VALNEVA SE SP.ADS/2 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VALNEVA SE SP.ADS/2 fundamental analysis

No fundamental analysis for VALNEVA SE SP.ADS/2 yet.

VALNEVA SE SP.ADS/2 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VALNEVA SE SP.ADS/2

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, …

Full company profile